Literature DB >> 9599864

Cost-effectiveness of measles outbreak intervention strategies.

A Shiell1, L R Jorm, R Carruthers, G J Fitzsimmons.   

Abstract

In this study, we compared the likely cost-effectiveness of alternative strategies for controlling a school-based measles outbreak. The analysis involved assessing the expected costs and number of cases in a school-based outbreak of measles, with no intervention and with each of six control strategies. The marginal cost per case prevented ranged from $32.90 when only previously unvaccinated school children were offered vaccination to $6795 when vaccination was extended to the siblings of school children aged 6 to 12 months. This study provided further evidence of the cost-effectiveness of vaccination in outbreak control, and yielded useful information to inform control strategies in the event of a school-based outbreak. Decisions about which groups of children to aim at and whether to conduct school-based clinics will be influenced by local circumstances, particularly the baseline measles vaccination rate and the measles attack rate among infants.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9599864     DOI: 10.1111/j.1467-842x.1998.tb01156.x

Source DB:  PubMed          Journal:  Aust N Z J Public Health        ISSN: 1326-0200            Impact factor:   2.939


  3 in total

Review 1.  Lessons from past pandemics: a systematic review of evidence-based, cost-effective interventions to suppress COVID-19.

Authors:  Carl-Etienne Juneau; Tomas Pueyo; Matt Bell; Genevieve Gee; Pablo Collazzo; Louise Potvin
Journal:  Syst Rev       Date:  2022-05-12

2.  How do government health departments in Australia access health economics advice to inform decisions for health? A survey.

Authors:  Lynne Madden; Lesley King; Alan Shiell
Journal:  Aust New Zealand Health Policy       Date:  2009-04-09

3.  The average cost of measles cases and adverse events following vaccination in industrialised countries.

Authors:  Hélène Carabin; W John Edmunds; Ulla Kou; Susan van den Hof; Van Hung Nguyen
Journal:  BMC Public Health       Date:  2002-09-19       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.